We are live on ! Find out more
GALTW

Galectin Therapeutics Inc. - Warrants

Delisted

GALTW was delisted on the 23rd of March, 2017.

5 hedge funds and large institutions have $123K invested in Galectin Therapeutics Inc. - Warrants in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+5
Holders Change %
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
1
Millennium Management
New York
$101K +$226K +640,800 New
Neuberger Berman Group
2
Neuberger Berman Group
New York
$20K +$44.3K +125,919 New
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$2K +$5.44K +15,450 New
TRCT
4
Tower Research Capital (TRC)
New York
+$47 +133 New
UBS Group
5
UBS Group
Switzerland
+$1.03K +2,912 New

GALTW Hedge Fund Activity: Q3 2016 in Review

5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics Inc. - Warrants (GALTW) for Q3 2016, worth a combined $123K.

Buyers outnumbered sellers: 5 funds opened new GALTW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $226K.

  • 5 institutional investors held Galectin Therapeutics Inc. - Warrants (GALTW) as of Q3 2016, up from 0 in Q2 2016.
  • Funds reported $123K of Galectin Therapeutics Inc. - Warrants stock for Q3 2016.
  • 5 funds opened new Galectin Therapeutics Inc. - Warrants positions in Q3 2016 and 0 closed out, a net change of +5 holders.
  • The largest Galectin Therapeutics Inc. - Warrants buyer in Q3 2016 was Millennium Management, an estimated $226K added.

Based on aggregated 13F filings for Q3 2016.